CV Sciences: What Went Wrong

|
About: CV Sciences, Inc. (CVSI)
by: Winds Research
This article is exclusive for subscribers.
Winds Research
Long/short equity, growth at reasonable price, long-term horizon, small-cap
Summary

CV Sciences has spent the last 12 months in free fall.

The company's Q3 2019 earnings results confirmed many fears selling shareholders would have had.

The pharmaceuticals division is a dud and needs to be divested.

Less than one year ago CV Sciences (OTCQB:CVSI) was trading at $6.25. The company, like Charlotte's Webb and Elixinol, the other companies in its space, were riding high on elevated valuations as investors